1873 logo

Viva Biotech Holdings Stock Price

SEHK:1873 Community·HK$4.2b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

1873 Share Price Performance

HK$1.97
0.30 (17.96%)
HK$1.97
0.30 (17.96%)
Price HK$1.97

1873 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with high growth potential.

2 Risks
4 Rewards

Viva Biotech Holdings Key Details

CN¥1.7b

Revenue

CN¥1.1b

Cost of Revenue

CN¥655.6m

Gross Profit

CN¥435.8m

Other Expenses

CN¥219.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
0.10
37.91%
12.71%
32.5%
View Full Analysis

About 1873

Founded
2008
Employees
2085
CEO
Chen Cheney Mao
WebsiteView website
www.vivabiotech.com.cn

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides research services. The company was incorporated in 2008 and is headquartered in Shanghai, China.

Recent 1873 News & Updates

Recent updates

No updates